DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$9.70
+14.66% today
Updated 2026-05-01
Market cap
$551.05M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-5.64
Dividend yield
—
52W range
$5 – $18
Volume
1.2M
Ginkgo Bioworks Holdings (DNA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-183.80%
Operating margin
-209.70%
ROE
-51.10%
ROA
-15.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $54.18M | $-119.33M | 100.00% | -132.14% | -220.23% |
| 2020 | $76.66M | $-126.61M | 79.64% | -178.75% | -165.16% |
| 2021 | $313.84M | $-1.83B | 58.68% | -582.62% | -583.12% |
| 2022 | $477.71M | $-2.10B | 57.25% | -462.41% | -440.63% |
| 2023 | $251.46M | $-892.87M | 78.52% | -343.76% | -355.08% |
| 2024 | $227.04M | $-547.03M | 83.02% | -246.54% | -240.94% |
| 2025 | $170.16M | $-312.76M | 81.48% | -185.29% | -183.81% |